Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Open-Label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-Small Cell Lung Cancer.

Next Previous
Search
Trial Profile

A Randomised Open-Label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-Small Cell Lung Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Volasertib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 28 May 2014 Planned End Date changed from 1 May 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
  • 25 Mar 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
  • 30 Oct 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top